Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Gene Therapy for CNS Disorders market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Gene Therapy for CNS Disordersmarket, defines the market attractiveness level of Gene Therapy for CNS Disorders market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Gene Therapy for CNS Disorders industry, describes the types of Gene Therapy for CNS Disorders market, the applications of major players and the market size, and deeply analyzes the current situation of the global Gene Therapy for CNS Disorders market and the development prospects and opportunities of Gene Therapy for CNS Disorders industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Gene Therapy for CNS Disorders market in Chapter 13.
By Player:
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio
By Type:
Ex Vivo
In Vivo
By End-User:
Hospitals
Clinics
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Gene Therapy for CNS Disorders Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Gene Therapy for CNS Disorders Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Gene Therapy for CNS Disorders Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Gene Therapy for CNS Disorders Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Gene Therapy for CNS Disorders Market Analysis and Outlook to 2022
-
7.1 Global Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.2 United States Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.3 Europe Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.4 China Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.5 Japan Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.6 India Gene Therapy for CNS Disorders Consumption (2017-2022)
-
7.7 South Korea Gene Therapy for CNS Disorders Consumption (2017-2022)
8 Region and Country-wise Gene Therapy for CNS Disorders Market Analysis and Outlook to 2028
-
8.1 Global Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.2 United States Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.3 Europe Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.4 China Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.5 Japan Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.6 India Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
-
8.7 South Korea Gene Therapy for CNS Disorders Consumption Forecast (2022-2028)
9 Global Gene Therapy for CNS Disorders Market Outlook by Types and Applications to 2022
-
9.1 Global Gene Therapy for CNS Disorders Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Ex Vivo Consumption and Growth Rate (2017-2022)
-
9.1.2 Global In Vivo Consumption and Growth Rate (2017-2022)
-
9.2 Global Gene Therapy for CNS Disorders Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Gene Therapy for CNS Disorders Market Outlook by Types and Applications to 2028
-
10.1 Global Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Ex Vivo Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global In Vivo Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Gene Therapy for CNS Disorders Import and Export Analysis (Top 5 Countries)
-
11.1 Global Gene Therapy for CNS Disorders Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Gene Therapy for CNS Disorders Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Gene Therapy for CNS Disorders Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Gene Therapy for CNS Disorders Market Competitive Analysis
-
14.1 Gilead (Kite Pharma)
-
14.1.1 Gilead (Kite Pharma) Company Details
-
14.1.2 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Product and Service
-
14.2 Amgen (BioVex)
-
14.2.1 Amgen (BioVex) Company Details
-
14.2.2 Amgen (BioVex) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Product and Service
-
14.3 Novartis
-
14.3.1 Novartis Company Details
-
14.3.2 Novartis Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Novartis Gene Therapy for CNS Disorders Product and Service
-
14.4 Roche (Spark Therapeutics)
-
14.4.1 Roche (Spark Therapeutics) Company Details
-
14.4.2 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Product and Service
-
14.5 Bluebird Bio
-
14.5.1 Bluebird Bio Company Details
-
14.5.2 Bluebird Bio Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Bluebird Bio Gene Therapy for CNS Disorders Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Gene Therapy for CNS Disorders
-
Figure Gene Therapy for CNS Disorders Picture
-
Table Global Gene Therapy for CNS Disorders Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Gene Therapy for CNS Disorders Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Gene Therapy for CNS Disorders Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Gene Therapy for CNS Disorders Consumption by Country (2017-2022)
-
Figure United States Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Table Europe Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Figure China Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Figure Japan Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Figure India Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Figure South Korea Gene Therapy for CNS Disorders Consumption and Growth Rate (2017-2022)
-
Figure Global Gene Therapy for CNS Disorders Consumption Forecast by Country (2022-2028)
-
Figure United States Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Gene Therapy for CNS Disorders Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ex Vivo Consumption and Growth Rate (2017-2022)
-
Figure Global In Vivo Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Ex Vivo Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global In Vivo Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Gene Therapy for CNS Disorders Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Gene Therapy for CNS Disorders Export by Region (Top 5 Countries) (2017-2028)
-
Table Gilead (Kite Pharma) (Foundation Year, Company Profile and etc.)
-
Table Gilead (Kite Pharma) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead (Kite Pharma) Gene Therapy for CNS Disorders Product and Service
-
Table Amgen (BioVex) (Foundation Year, Company Profile and etc.)
-
Table Amgen (BioVex) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen (BioVex) Gene Therapy for CNS Disorders Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Gene Therapy for CNS Disorders Product and Service
-
Table Roche (Spark Therapeutics) (Foundation Year, Company Profile and etc.)
-
Table Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Product and Service
-
Table Bluebird Bio (Foundation Year, Company Profile and etc.)
-
Table Bluebird Bio Gene Therapy for CNS Disorders Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bluebird Bio Gene Therapy for CNS Disorders Product and Service
-
